drugset / Trial / NCT00035828

A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD

NCT00035828 ↗

Phase 2 Completed 150 enrolled Abgenix
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if ABX-IL8 will improve shortness of breath.

Timeline

Start
2001-12
Primary completion
—
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ABX-IL8 Monoclonal antibody — —

Indications